ASND Stock Risk & Deep Value Analysis
Ascendis Pharma A/S
DVR Score
out of 10
What You Need to Know About ASND Stock
We analyzed Ascendis Pharma A/S using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ASND through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ASND Risk Analysis & Red Flags
What Could Go Wrong
Ascendis Pharma is still heavily reliant on pipeline success and efficient commercialization for multiple new products while remaining loss-making. If key pipeline assets like TransCon CNP face regulatory delays or commercialization hurdles, or if the ongoing patent litigation with BioMarin results in an unfavorable outcome, the significant R&D expenses and cash burn could lead to further substantial losses and require additional dilutive financing before profitability is achieved.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Remains a loss-making company, requiring continued investment in R&D and commercialization.
- ⚠
Dilution from warrant exercises (399,438 new shares issued Mar 30, 2026).
- ⚠
Ongoing, costly patent litigation with key competitor BioMarin.
- ⚠
Specific balance sheet and cash flow details are not fully transparent in provided intelligence.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss (revenue or EPS)
- 📅
Negative clinical trial readouts for pipeline assets (e.g., TransCon CNP)
- 📅
Adverse outcome in ongoing patent litigation with BioMarin
When to Reconsider
- 🚪
Significant deceleration in SKYTROPHA sales growth or unexpected negative TransCon PTH commercialization data.
- 🚪
Clear negative clinical trial data for TransCon CNP or other late-stage pipeline assets.
- 🚪
Unfavorable judgment in the BioMarin patent litigation that impacts key product candidates.
Unlock ASND Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Ascendis Pharma is a high-growth biotech leveraging its proprietary TransCon platform to develop and commercialize a diversified portfolio of innovative therapies. With SKYTROPHA's proven success, the expected significant ramp-up of TransCon PTH, and a robust late-stage pipeline in areas like achondroplasia and oncology, the company is strategically positioned for multiple blockbuster franchises and substantial market share gains, justifying its aggressive growth valuation.
Is ASND Stock Undervalued?
Unlock the full AI analysis for ASND
Get the complete DVR score, risk analysis, and more
ASND Price Targets & Strategy
12-Month Target
$290.00
Bull Case
$330.00
Bear Case
$200.00
Valuation Basis
Based on 25x estimated FY2026 P/S applied to projected $700M FY2026 revenue, yielding an approximate market cap of $17.5B.
Entry Strategy
Dollar-cost average on dips, targeting the $210-$220 range, watching for stability post-earnings.
Exit Strategy
Consider partial profit-taking at $290, with a target exit at $330. Implement a stop loss at $200.
Portfolio Allocation
7-15% for aggressive risk tolerance, reflecting high growth potential balanced by biotech sector volatility.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ASND Financially Healthy?
Valuation
P/E Ratio
-52.50
Forward P/E
19.93
Price/Sales
16.85
Profitability
Gross Margin
84.81%
EPS
$-0.64
Other
Beta (Volatility)
0.43
Does ASND Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The TransCon platform's innovative drug delivery (sustained release, less frequent dosing) provides a significant advantage over conventional therapies, making it difficult for competitors to replicate without substantial R&D and regulatory hurdles, ensuring durability for 10-20 years.
Moat Erosion Risks
- •Patent expiry or successful challenges to key TransCon patents, particularly from competitors like BioMarin.
- •Emergence of superior or equally effective drug delivery technologies or new therapeutic modalities.
- •Intense competition from established pharmaceutical companies with significant resources.
ASND Competitive Moat Analysis
Sign up to see competitive advantages
ASND Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data, but positive analyst outlook suggests underlying optimism.)
Institutional Sentiment
Positive (Moderate Buy consensus with 17 Buy ratings; recent analyst upgrades and increased price targets, e.g., Stifel at $332, RBC at $275.)
Insider Activity (Form 4)
Singel Stina (Officer) proposed sale of 3,782 shares ($907,680) on Mar 9, 2026. Imani Siham (Director) proposed sale of 1,800 shares ($435,762) on Mar 2, 2026.
Options Flow
Normal options activity (No specific unusual activity reported in research data.)
Earnings Intelligence
Next Earnings
Estimated May 2026
Surprise Probability
Medium (Q4 2025 saw a revenue beat but a significant EPS miss, indicating sensitivity to expense management.)
Historical Earnings Pattern
Mixed reactions to past earnings, with a revenue beat and EPS miss in Q4 2025, suggesting investor focus on top-line growth and pipeline progression over immediate profitability.
Key Metrics to Watch
Competitive Position
Top Competitor
BMRN
Market Share Trend
Gaining (SKYTROPHA gaining traction, TransCon PTH and CNP expected to capture new markets).
Valuation vs Peers
Trading at a significant premium on P/S (~48x TTM) due to high growth expectations and pipeline value, which is common for innovative platform biotechs.
Competitive Advantages
- •Proprietary TransCon drug delivery platform offering sustained, predictable drug exposure.
- •Robust and diversified pipeline addressing high-unmet-need rare diseases and oncology.
- •Proven commercial execution with SKYTROPHA.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ASND Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (expected May 2026)
- •Updates on TransCon PTH commercialization progress and uptake
- •Pipeline updates, particularly for TransCon CNP in achondroplasia
Medium-Term (6-18 months)
- •TransCon CNP (achondroplasia) regulatory milestones and potential approval
- •Advancement of oncology pipeline assets into later-stage clinical trials
- •Expansion of SKYTROPHA into new geographies or indications
Long-Term (18+ months)
- •Broad application of TransCon platform across new therapeutic areas
- •Establishment as a multi-franchise leader in rare diseases and oncology
- •Significant global market penetration for key approved products
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ASND?
- ✓
Acceleration in SKYTROPHA sales growth and better-than-expected TransCon PTH market penetration.
- ✓
Positive clinical and regulatory updates for TransCon CNP and other pipeline assets.
- ✓
Management commentary on cash burn control and progress towards profitability.
Bull Case Analysis
See what could go right with Premium
Competing with ASND
See how Ascendis Pharma A/S compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Ascendis Pharma A/S ASND | $14.3B | 8.7 | -52.5 | — | 0.0% | 0.0% |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Ascendis Pharma A/S (ASND)?
As of April 3, 2026, Ascendis Pharma A/S has a DVR Score of 8.7 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Ascendis Pharma A/S?
Ascendis Pharma A/S's market capitalization is approximately $14.3B..
What is the risk level for ASND stock?
Our analysis rates Ascendis Pharma A/S's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ASND?
Ascendis Pharma A/S currently has a price-to-earnings (P/E) ratio of -52.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Ascendis Pharma A/S's revenue growing?
Ascendis Pharma A/S has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ASND stock profitable?
Ascendis Pharma A/S has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ASND DVR analysis updated?
Our AI-powered analysis of Ascendis Pharma A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ASND (Ascendis Pharma A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.